STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
Peter Ferenci, Tarik Asselah, Graham R Foster, Stefan Zeuzem, Christoph Sarrazin, Christophe Moreno, Denis Ouzan, Marina Maevskaya, Filipe Calinas, Luis E Morano, Javier Crespo, Jean-François Dufour, Marc Bourlière, Kosh Agarwal, Daniel Forton, Marcus Schuchmann, Elmar Zehnter, Shuhei Nishiguchi, Masao Omata, George Kukolj, Yakov Datsenko, Miguel Garcia, Joseph Scherer, Anne-Marie Quinson, Jerry O Stern, STARTVerso1 Study Group, Peter Ferenci, Tarik Asselah, Graham R Foster, Stefan Zeuzem, Christoph Sarrazin, Christophe Moreno, Denis Ouzan, Marina Maevskaya, Filipe Calinas, Luis E Morano, Javier Crespo, Jean-François Dufour, Marc Bourlière, Kosh Agarwal, Daniel Forton, Marcus Schuchmann, Elmar Zehnter, Shuhei Nishiguchi, Masao Omata, George Kukolj, Yakov Datsenko, Miguel Garcia, Joseph Scherer, Anne-Marie Quinson, Jerry O Stern, STARTVerso1 Study Group
Abstract
Background & aims: The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon (PegIFN) and ribavirin (RBV) was assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve patients with HCV genotype-1 infection.
Methods: Patients were randomly assigned (1:2:2) to PegIFN/RBV plus: placebo (arm 1, n = 132) for 24 weeks; faldaprevir (120 mg, once daily) for 12 or 24 weeks (arm 2, n = 259); or faldaprevir (240 mg, once daily) for 12 weeks (arm 3, n = 261). In arms 2 and 3, patients with early treatment success (HCV-RNA <25 IU/ml at week 4 and undetectable at week 8) stopped all treatment at week 24. Other patients received PegIFN/RBV until week 48 unless they met futility criteria. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12).
Results: SVR12 was achieved by 52%, 79%, and 80% of patients in arms 1, 2, and 3, respectively (estimated difference for arms 2 and 3 vs. arm 1: 27%, 95% confidence interval 17%-36%; and 29%, 95% confidence interval, 19%-38%, respectively; p < 0.0001 for both). Early treatment success was achieved by 87% (arm 2) and 89% (arm 3) of patients, of whom 86% and 89% achieved SVR12. Adverse event rates were similar among groups; few adverse events led to discontinuation of all regimen components.
Conclusions: Faldaprevir plus PegIFN/RBV significantly increased SVR12, compared with PegIFN/RBV, in treatment-naïve patients with HCV genotype-1 infection. No differences were seen in responses of patients given faldaprevir once daily at 120 or 240 mg.
Trial registration: ClinicalTrials.gov NCT01343888.
Keywords: Clinical trial; DAA; Early treatment success; NS3/4A protease inhibitor; Phase 3; SVR12.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Source: PubMed